General Cancer
Atezolizumab Falls Short in High-Risk HNSCC
The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
Second Analysis of FLAURA2 Extends Benefit of Osimertinib Combo in NSCLC
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Phase 3 SunRISe-2 Study Investigates Novel TAR-200 Therapy in Muscle Invasive Bladder Cancer
Stephen Williams, MD, MBA, MS, FACS, FACHE, discussed updates from the SunRISe-2 study investigating TAR-200 plus cetrelimab vs chemotherapy in muscle invasive bladder cancer.
Subcutaneous Atezolizumab Is Equivalent to Intravenous Formulation in NSCLC
Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.